257953-75-6

Upstream product

• 764698-14-8 ethyl (2E)-(5-oxopiperazin-2-ylidene)ethanoate 
• 2566-19-0 CbzGlyGly 
• 257953-71-2 ethyl 4-[N-(benzyloxycarbonyl)glycyl]amino-3-oxobutanoate 

Downstream Products

• 943342-50-5 5-(1'-ethoxycarbonyl)methyl-4-(N-phenyl)carbamoyl-piperazin-2-one 
• 828926-32-5 2-(5-oxo-1-tosylpiperazin-2-yl)acetic acid 
• 828926-31-4 ethyl 2-(5-oxo-1-tosylpiperazin-2-yl)acetate 
• 764698-17-1 ethyl {1-[(3-chlorophenyl)sulfonyl]-5-oxopiperazin-2-yl}acetate 
• 943342-54-9 7-phenyl-4-H-tetrahydropyrazino[1,2-f]pyrimidine-3,6,8-trione 
• 943342-60-7 6-(tert-butoxycarbonyl)aminomethyl-1-(methoxycarbonyl)methyl-3-phenyltetrahydropyrimidine-2,4-dione 
• 943342-57-2 2-tert-butoxycarbonyl-7-phenyl-4H-tetrahydropyrazino[1,2-f]pyrimidine-3,6,8-trione 

Relevant academic research and scientific papers

KETOPIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS

Ketopiperazine derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

Stereoselective reductive amination of β-keto esters derived from dipeptides. Stereochemical and mechanistic studies on the formation of 5-carboxymethyl-2-oxopiperazine derivatives

The stereoselective generation of 3,5-disubstituted and 3,5,6-trisubstituted 2-oxopiperazine derivatives can be accomplished by intramolecular reductive amination of β-keto esters derived from Z-Xaa-Gly-OH and Z-Xaa-Yaa-OH dipeptides, respectively. Differences in the stereoselectivity between the use of NaBH3CN and hydrogen as reducing agents are due to the reduction of different intermediates, as deduced from experiments of isotopic labelling with deuterium.